Dr. Charles N. Soparkar, MD, PhD

Dr. Soparkar practices at Plastic Eye Surgery Associates in Houston, Texas.

Dr. Soparkar's NPI, 1659464550, was assigned on October 2, 2006. Dr. Soparkar graduated from UMass Chan Medical School in 1990. Dr. Soparkar holds Texas license J6247.

Dr. Soparkar's primary practice is Plastic Eye Surgery Associates, at 3730 Kirby Dr, Houston, TX 77098. The practice phone is (713) 795-0705.

Dr. Soparkar's primary practice is Plastic Eye Surgery Associates in Houston, Texas. Dr. Soparkar is also affiliated with Houston Methodist Hospital. Dmand AI also links Dr. Soparkar to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soparkar practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Soparkar's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Soparkar is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Soparkar's licenses on file in 4 states: Texas, Florida, Massachusetts and Pennsylvania.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and vision problems among the conditions Dr. Soparkar treats.

CMS data shows 10,916 Medicare services from Dr. Soparkar across 18 procedure codes in 2024, for 351 Medicare patients. Medicare paid $357,169 for them.

CMS counts 351 Medicare patients who saw Dr. Soparkar in 2024. The largest group is 65 to 74, with 191 patients. 74% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Soparkar's median patient age at 68, with 66% women.

In 2024, Dr. Soparkar wrote 1,024 Medicare Part D claims for 293 patients. 93% of them were for generic drugs. CMS names the drug for 953 of them, across 9 drugs with 11 or more claims each, at $5,876 in total drug cost. In 2023, CMS named 973 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Soparkar for performance year 2024, reported individually. Dr. Soparkar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 89 procedures of melanoma (skin cancer) excision by Dr. Soparkar, more than 92% of the clinicians it reports for that procedure.

Dmand AI links 58 papers to Dr. Soparkar, published from 2001 to 2021. 2011 was the busiest year, with 2. The most frequent topics are Tomography, X-Ray Computed, Eyelids and Orbit. Dr. Soparkar has published most often in Ophthalmic Plast Reconstr Surg. Dr. Soparkar's most frequent co-authors are James Randall Patrinely, MD, Forrest Sussman Roth, MD and Eugene Landon Alford, MD.

CMS Open Payments shows 129 general payments to Dr. Soparkar from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Revance Therapeutics, Inc. paid the most, $1,165.

Dmand AI lists 6 awards for Dr. Soparkar, most recently America's Top Doctors in 2014.

Dr. Soparkar graduated from UMass Chan Medical School in 1990. Dr. Soparkar is a member of AAO and ACS.

Dr. Soparkar is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.